Form D · Biotechnology

Avant Diagnostics, Inc

Washington, DC · CIK 0001451929

Offering snapshot reported Jun 13, 2018 · SEC filing

Reported sold
$1.17M
Offering amount: $2M
Investors reported
8
Form D · investor count
Minimum accepted
$100K
Reported outside-investor minimum
First sale
May 25, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 13, 2018Initial$1,165,155No comparison8SEC filing
Jan 20, 2016Initial$112,500No comparison1SEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$52K
Finders' fees
$0
Form D file number
021-314464
Includes an aggregate of $516,155 of existing indebtedness exchanged for Series A Preferred Stock.
Series A Preferred Stock. The minimum amount disclosed in Item 11 may be modified by the Issuer in its sole discretion.
Does not include warrants issued to the agent.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Dominick & Dickerman LLC21076

Source: Form D, filed Jun 13, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
John Brugmann Director
Jeff Busch Director
Randall Letcavage Director
Gregg Linn Director, Executive
Joseph Roth Director
Michael Ruxin, M.D. Executive
Jeff Stephens Director
Robert Trapp Director
Scott Vander Meer Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1050 30 Th Street Nw, Suite 107
Washington, DC, 20007